• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature >Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
【24h】

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

机译：他汀类药物治疗与肠道微生物症失育症的较低率较低有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.
机译：摘要微生物组群落打字分析最近鉴定了与系统性炎症有关的肠道微生物液，肠道微生物A型肠溶型，在人类1,2中的松散粪便中具有高普遍性。 Bact2的特征在于拟枝杆菌比例，粪便比例低，微生物细胞密度为1,2，其流行率在炎症性肠病患者中的一般人群群组中的13％变化为高达78％。报道粪便一致性的变化和炎症状态4在肥胖和代谢可公司的进展期间导致我们提出这些发育可能与潜在的疑难生Bact2肠型的患病率同样相关。这里，通过探索腹部粪便群体质量指数谱队列（n = 888）的定量粪便群体中的肥胖相关的微生物A改变，我们将他汀类药物鉴定为微生物组多样化的关键协变量。通过专注于没有用他汀类药物药物药物的参与者的子跳组成，我们发现Bact2的患病率与体重指数相关，从贫血或超重参与者的3.90％增加到肥胖参与者中的17.73％。 Bact2-Enter型个体中的全身炎症水平高于其肥胖状态的预测，指示Bact2作为疑难生微生物组星座。我们还观察到肥胖相关的微生物瘤功能生物症与他汀类药物治疗负相关，导致他汀类药物肥胖参与者的较低的Bact2患病率为5.88％。该发现在伴随的Metacardis心血管疾病数据集（n = 282）和独立佛氏肠道菌群项目人口群（n = 2,345）中。他汀类药物在这种情况下的潜在益处将需要进一步评估前瞻性临床试验，以确定效果是否在随机群体中可重现，并在考虑其作为微生物群调制治疗剂的应用。

著录项

  • 来源
    《Nature》 |2020年第7808期|310-315|共6页
  • 作者

  • 作者单位
  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号